Danaher Corp. is snapping up patient monitoring medtech Masimo in a $9.9 billion deal aimed at strengthening its diagnostics ...

Danaher Corporation (NYSE: DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) a leading ...

On February 17, 2026, Danaher announced a definitive agreement to acquire Masimo Corporation, a specialty diagnostics company known for pulse oximetry and patient monitoring solutions used primarily ...

Danaher is acquiring Masimo for $9.9B, integrating its patient monitoring innovations to enhance diagnostics and drive growth in acute care settings.

The move reflects a broader industry shift toward consolidation and integrated care, as large healthcare companies seek scale ...

Masimo Corporation agreed to be acquired by Danaher for $180/share, valuing MASI at $9.9B. Click here to read my most recent analysis covering the acquisition.

Masimo stock jumps as it agrees to be acquired by Danaher. The company is perhaps best known for its yearslong patent dispute with Apple.

Masimo’s board considered other potential partners before determining Danaher was an “ideal fit,” executives at the patient ...

Medtronic and Mindray North America expanded their partnership on patient monitoring technology beyond hospitals into ASCs in ...

In an observational study that began enrollment last month, researchers will determine if continuous, remote lung sound ...

The Financial Times reports that Danaher is on the verge of acquiring Masimo in a deal worth approximately $9.9 billion.

Authors say findings highlight the need for more convenient, less burdensome monitoring tools. HealthDay News — Individuals with hypertension are unlikely to measure their blood pressure (BP) at home ...